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ABSTRACT
AD (Alzheimer’s disease) is a neurodegenerative disease and
the most common form of dementia. One of the pathological
hallmarks of AD is the aggregation of extracellular Abs
(amyloidb-peptides)insenileplaquesinthebrain.Theprocess
could be initiated by seeding provided by an interaction
between GM1 ganglioside and Abs. Several reports have
documentedthebifunctionalrolesofAbsinNSCs(neuralstem
cells),butthepreciseeffectsofGM1 andAbonNSCshavenot
yet been clarified.Weevaluated the effectofGM1 and Ab-(1–
40)onmouseNECs(neuroepithelialcells),whichareknownto
be rich in NSCs. No change of cell number was detected in
NECs cultured in the presence of either GM1 or Ab-(1–40). On
thecontrary,adecreasednumberofNECswereculturedinthe
presence of a combination of GM1 and Ab-(1–40). The
exogenously added GM1 and Ab-(1–40) were confirmed to
incorporate into NECs. The Ras–MAPK (mitogen-activated
protein kinase) pathway, important for cell proliferation, was
intact in NECs simultaneously treated with GM1 and Ab-(1–
40), but caspase 3 was activated. NECs treated with GM1 and
Ab-(1–40)werepositive inthe TUNEL (terminal deoxynucleo-
tidyl transferase-mediated dUTP nick-end labelling) assay, an
indicator of cell death. It was found that GM1 and Ab-(1–40)
interacted in the presence of cholesterol and sphingomyelin,
componentsofcellsurfacemicrodomains.Thecytotoxiceffect
was found also in NSCs prepared via neurospheres. These
resultsindicatethatAb-(1–40)andGM1co-operativelyexerta
cytotoxic effect on NSCs, likely via incorporation into NEC
membranes, where they form a complex for the activation of
cell death signalling.
Key words: Alzheimer’s disease (AD), amyloid b-peptide (Ab),
apoptosis,GM1ganglioside,glycosphingolipid,neuralstemcell.
INTRODUCTION
AD (Alzheimer’s disease), the most common form of
dementia, is a neurodegenerative disease that manifests
clinically as progressive memory loss and cognitive impair-
ment. Pathologically, it is characterized by the appearance of
senile plaques and neurofibrillary tangles and loss of neurons
in the cerebral cortex (Ariga et al., 2008). Elucidation of the
pathogenesis of AD, which is not yet fully understood, is an
important subject for the development of therapies for this
disease. One of the pathological hallmarks and possible causes
of AD is the aggregation and accumulation of extracellular
Abs (amyloid b-peptides) in the brain. Abs, which are
produced from amyloid precursor protein by sequential
endoproteolytic cleavages by b-secretase and c-secretase,
are originally monomeric, soluble and non-toxic, but become
cytotoxic by aggregation and accumulation. Senile plaques
seen in the brains of AD patients are mainly composed of the
aggregated and accumulated Abs. The aggregation of Abs, a
critical step in the onset of AD, has been proposed to be ini-
tiated by GM1 ganglioside (Hayashi et al., 2004; Yanagisawa,
2007).
Gangliosides, sialic acid-containing glycosphingolipids, are
ubiquitously expressed in vertebrate cells and body fluids, and
are particularly abundant in the nervous system (Yu et al.,
2009).Incells,gangliosidesarelocalizedprimarily,althoughnot
exclusively,ontheplasma membrane.Togetherwithcholesterol
and sphingomyelin, gangliosides are components of cell surface
microdomains (glycosphingolipid-enriched microdomains,
caveolae or lipid rafts). These specialized microdomain struc-
tures have been suggested to serve as important platforms for
modulating cell adhesion and signal transduction. In AD brains,
GM1 ganglioside, one of the major brain gangliosides, is
considered to bind to monomeric Abs and initiate their
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(Hayashi et al., 2004; Yanagisawa, 2007). On the other hand,
gangliosides are widely known to have neuroprotective effects
(Svennerholm, 1994; Ledeen and Wu, 2002; Svennerholm et al.,
2002). Certain gangliosides, including GM1,h a v ea l s ob e e n
reported to inhibit Ab-induced secretion of pro-inflammatory
cytokines such as IL-1b (interleukin-1b), IL-6 and tumour
necrosis factor-a, which are involved in the pathogenic events
of AD (Ariga and Yu, 1999; Ariga et al., 2001a). Understanding
the relationship between Ab and GM1 and their bidirectional
effects is important to fully elucidate the pathogenesis
of AD.
At present, there is still no well-established cure for AD.
The strategy of using endogenous or transplanted NSCs
(neural stem cells) to compensate for the neuronal loss in AD
brains has been proposed. Because of their basic biological
importance and latent clinical usefulness for treating a
variety of neurodegenerative diseases (such as AD), NSCs
(which are undifferentiated neural cells that are endowed
with a high potential for proliferation and the capacity for
self-renewal retaining the multipotency to differentiate into
neuronal and glial cells) have been of great interest during
the last two decades (Sugaya, 2003). In adult mammalian
brains, NSCs are localized in the subventricular zone of the
lateral ventricles and the subgranular layer of the dentate
gyrus in the hippocampus. Nevertheless, neurogenesis in
these areas does not compensate for neuronal loss in AD
brains, implying the possibility that this impairment of
neurogenesis, especially in the hippocampal dentate gyrus, is
involved in the pathogenesis of AD. So far, several reports
have documented the bifunctional roles of Abs in NSCs in
vitro;A bs have neurogenic effects in some studies (Lopez-
Toledano and Shelanski, 2004; Waldau and Shetty, 2008;
Chen and Dong, 2009; Sotthibundhu et al., 2009), but
cytotoxic effects in other studies (Haughey et al., 2002a,
2002b; Millet et al., 2005; Calafiore et al., 2006; Waldau and
Shetty, 2008). However, the effects of a combination of Ab
and GM1 on NSCs have not yet been clarified. In the present
study, we evaluated the effects of GM1 and Ab-(1–40), the
isoform of 40 amino acid residues in length, on mouse NEC
(neuroepithelial cell), which are known to be rich in NSCs
(Fukuda et al., 2007).
MATERIALS AND METHODS
Materials
The GM1 ganglioside used in the present study was isolated
from human brain in our laboratories (Ledeen and Yu, 1982).
Ab-(1–40) was purchased from Bachem Americas (Torrance,
CA, U.S.A.; catalogue number H-1194.0001; lot number
2500610). Tunicamycin, an inhibitor of N-linked glycosylation,
was purchased from Sigma–Aldrich (St Louis, MO, U.S.A.).
NEC culture
NECs were prepared from telencephalons of mouse embryos
(embryonic day 14.5) and cultured in N2-DMEM/F12 [N2-
supplemented DMEM (Dulbecco’s modified Eagle’s medium)/
Ham’s Nutrient Mixture F12] containing bFGF (basic fibroblast
growth factor; Peprotech, Rocky Hill, NJ, U.S.A.) on dishes
coated with poly-L-ornithine and fibronectin (Sigma–Aldrich)
by the method described by Nakashima et al. (1999). Mice used
for the cell preparation were treated according to the
guidelines of the IACUC (Institutional Animal Care and Use
Committee)ofthe MedicalCollegeofGeorgia tominimizepain
or discomfort. NECs cultured for 6 days were replated for
treatment with GM1 and/or Ab-(1–40). For treatment of NECs,
GM1 was completely dried under a stream of nitrogen and then
dissolved in N2-DMEM/F12 at 37˚C. Ab-(1–40) dissolved in PBS
and stored at 280˚C as a stock solution was directly added to
N2-DMEM/F12 immediately before treatment of NECs; any
procedures to induce the formation of the oligomeric or
fibrillary form of Ab-(1–40) were not performed. The NECs
treated with GM1 and/or Ab-(1–40) were used for the
experiments described below.
WST-8 assay
The number of cells cultured in the presence or absence of
GM1 and/or Ab-(1–40) on poly-L-ornithine- and fibronectin-
coated 96-well plates for 4 days was estimated by the WST-8
assay, a highly sensitive and reproducible method (Kanemura
et al., 2002; Yu and Yanagisawa, 2007; Yanagisawa and Yu,
2009), using a Cell Counting Kit-8 (Dojindo, Kumamoto,
Japan). The A450 of WST-8-formazan produced by the
dehydrogenase activity in the living cells was measured
(reference: 650 nm) using a Benchmark Plus microplate
spectrophotometer (Bio-Rad Laboratories, Hercules, CA,
U.S.A.).
Cell staining
NECs cultured in N2-DMEM/F12 containing GM1 and/or Ab-(1–
40) or FITC-Ab-(1–40) [FITC-conjugated Ab-(1–40); Bachem
Americas] on chamber slides (Nalge Nunc International,
Naperville, IL, U.S.A.) for 2 or 3 days were fixed in PBS
containing 4% (w/v) paraformaldehyde and stained with
biotin-Ctxb (biotin-conjugated cholera toxin B subunit), rat
401 anti-nestin monoclonal antibody (BD Biosciences, San
Jose, CA, U.S.A.) or anti-b-III tubulin monoclonal antibody
(Sigma–Aldrich). Biotin-Ctxb and monoclonal antibodies were
detected with rhodamine-conjugated streptavidin (Jackson
ImmunoResearch, West Grove, PA, U.S.A.) and Alexa FluorH
488-conjugated anti-mouse IgG antibody (Invitrogen,
Carlsbad, CA, U.S.A.) respectively. Nuclei were stained with
Hoechst 33258 (Sigma–Aldrich). The stained NECs were
photographed under a Nikon Eclipse TE300 fluorescent
microscope (Nikon Instruments, Melville, NY, U.S.A.) equipped
with a Magnafire digital CCD camera (charge-coupled device
camera; Optronics, Goleta, CA, U.S.A.).
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Western-blot analysis was performed as previously described
(Yanagisawa and Yu, 2009). As primary antibodies, anti-
phospho-ERK (extracellular-signal-regulated kinase) mono-
clonal antibody (Cell Signaling Technology, Danvers, MA,
U.S.A.), anti-ERK polyclonal antibody (Santa Cruz Biotech-
nology, Santa Cruz, CA, U.S.A.), anti-p27
Kip1 monoclonal
antibody (BD Biosciences), anti-b-actin monoclonal antibody
(Sigma–Aldrich)and anti-caspase3rabbitmonoclonalantibody
(Cell Signaling Technology) were used. Horseradish-peroxidase-
conjugatedanti-mouseIgGantibody(GEHealthcareLifeSciences,
Piscataway, NJ, U.S.A.) and anti-rabbit IgG antibody (GE
Healthcare Life Sciences) were used as the secondary antibodies.
Protein bands reacted with the antibodies were detected using
WesternLightning Western Blot Chemiluminescence Reagent
Plus (PerkinElmer Life and Analytical Sciences, Waltham, MA,
U.S.A.).
RT–PCR (reverse transcription–PCR)
RT–PCR was performed as previously described (Ngamukote
et al., 2007). The sequences of primer sets were as follows: 59-
TGGAAGTGGCTACATACAGGAC-39 and 59-GGTATTAGGCAAG-
GGGGAAG-39 for nestin; 59-CCTCAGCTGACAGAGAAACAG-39
and 59-CTTGGTTCTGTGCTCTGTTTTC-39 for MAP2 (micro-
tubule-associated protein 2); 59-ACCACAGTCCATGCCATCAC-39
and 59-TCCACCACCCTGTTGCTGTA-39 for GAPDH (glyceralde-
hyde-3-phosphate dehydrogenase).
TUNEL (terminal deoxynucleotidyl transferase-
mediated dUTP nick-end labelling)
Apoptotic cells were detected with the TUNEL assay. In brief,
cells were plated on to chamber slides and cultured in N2-
DMEM/F12 containing GM1 and Ab-(1–40) in the presence of
5 ng/ml of bFGF for 3 days. Then, the cells were fixed in PBS
containing 4% paraformaldehyde for 1 h at room temper-
ature (approx. 25˚C) and permeabilized in 0.1% sodium
citrate containing 0.1% Triton X-100 for 2 min at 4˚C. The
cells were incubated with fluorescein-conjugated TUNEL
reaction mixture (Roche Diagnostics, Mannheim, Germany)
for 2 h at 37˚C. Nuclei were stained with Hoechst 33258.
Stained cells were photographed under a Nikon Eclipse TE300
fluorescent microscope equipped with a Magnafire digital
CCD camera.
GM1 binding assay
Physical interaction between GM1 and Ab-(1–40) was revealed
by a GM1 binding assay using GM1-coated 96-well plates and
FITC-Ab-(1–40). In brief, polystyrene 96-well white plates
(Nalge Nunc International) were coated with GM1 by adding a
methanolic solution of GM1 (0, 1 or 10 nmol per well) and/or
cholesterol (Sigma–Aldrich; 0 or 7.5 nmol per well) and
sphingomyelin (Sigma–Aldrich; 0 or 7.5 nmol per well) to each
well; the molar proportion of the lipids was 40:30:30 (GM1/
cholesterol/sphingomyelin) (Kakio et al., 2001). After the
methanol solvent had been evaporated at 37˚C, a blocking
solution of PBS containing 1% BSA was added. GM1
immobilized on the wells was incubated with Hanks buffered
saline solution containing 5 mM of an FITC-Ab-(1–40) solution
in the dark for 1 h at room temperature. After washing, the
fluorescent intensity of FITC-Ab-(1–40) binding to GM1
immobilized on the wells was measured using a Victor
3 V
multilabel plate reader (PerkinElmer Life and Analytical
Sciences) equipped with a lex5485 nm filter and a lem5535
nm filter. To evaluate the efficiency of the assay, the
polystyrene 96-well plates coated with GM1 (0, 1, 10, 100
and 1000 pmol per well) were incubated with 1 mM of biotin-
Ctxb and then 2 mg/ml of Cy2-conjugated streptavidin
(Jackson ImmunoResearch).
NSC culture
NSCs were prepared in the form of neurospheres, floating
clonal aggregates formed by NSCs in vitro, according to
previously described methods but with slight modifications
(Reynolds et al., 1992; Nakatani et al., 2010). In brief, single-
cell suspensions prepared from striata of mouse embryos
(embryonic day 14.5) by mechanical trituration were cultured
in N2-DMEM/F12 containing 20 ng/ml bFGF and 20 ng/ml
epidermal growth factor (Peprotech). Neurospheres formed
after 1 week were collected for passage or further analyses.
Confirmation of NSCs was performed by cell staining using a
subclass control IgG (BD Biosciences) or anti-nestin mono-
clonal antibody.
RESULTS
First, we examined the number of NECs treated with low
concentrations of GM1 and Ab-(1–40). As shown in Figure 1,
lower concentrations of GM1 (1, 5 or 10 mM) and/or Ab-(1–
40) (1 or 5 mM) have almost no effect on the NEC number. It
has been reported that the effect of Ab on NSCs is highly
dependent on the concentration; monomeric Ab showed no
significant effect on proliferation and differentiation of adult
mouse NSCs at lower concentrations, but inhibited the
proliferation and neurogenesis at higher concentrations (Heo
et al., 2007). Therefore we evaluated the effects of higher
concentrations of GM1 and Ab-(1–40) by culturing NECs in
the presence of 40 mMG M1 and 10 mMA b-(1–40) on NECs.
Neither 40 mMG M1 nor 10 mMA b-(1–40) affected the NEC
number (Figure 2). However, in NECs cultured in the presence
of both 40 mMG M1 and 10 mMA b-(1–40), a significant
reduction in the cell number was detected (Figure 2). This
result indicates that Ab-(1–40) in the presence of GM1 has a
cytotoxic effect on NECs.
Generally, gangliosides exogenously added to tissue culture
have been expected to be incorporated into the cell
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51membranes through the hydrophobic ceramide residues.
However, it is unclear whether exogenously added GM1 and
Ab-(1–40) were incorporated into NECs. Taking advantage of
barely detectable quantities of GM1 expressed in NECs
(Yanagisawa et al., 2006a), we evaluated the incorporation
of GM1 into the NECs by staining with Ctxb, a probe recog-
nizing GM1 and other related gangliosides. Simultaneously,
Ab-(1–40) distribution was examined by culturing NECs with
FITC-Ab-(1–40). As shown in Figure 3, GM1-treated NECs
showed a strong reactivity to Ctxb. In addition, a strong FITC
signal was found in NECs treated with FITC-Ab-(1–40). These
results indicate that exogenously added GM1 and Ab-(1–40)
were efficiently incorporated into NECs. In the NECs
simultaneously treated with GM1 and Ab-(1–40), however,
there was no difference in their fluorescence intensities.
Therefore it was confirmed that the co-operative effect of
GM1 and Ab-(1–40) on the number of NECs is mediated after
the incorporation into NECs.
We then analysed the molecular mechanism underlying the
reduction of the NEC number by GM1 and Ab-(1–40). The Ras–
MAPK (mitogen-activated protein kinase) pathway is known to
be essential for the proliferation of NECs (Yanagisawa et al.,
2005). In NECs treated with GM1 and/or Ab-(1–40), however,
bFGF-induced activation of the Ras–MAPK pathway was intact
(Figure 4A). A cyclin-dependent kinase inhibitor, p27
Kip1,
which has been suggested to be up-regulated by ganglioside
stimulation and involved in ganglioside-induced inhibition of
neural cell proliferation (Nakatsuji and Miller, 2001), was not
up-regulated in NECs treated with GM1 and/or Ab-(1–40)
(Figure 4B). These results indicate that GM1 and Ab-(1–40) did
not inhibit the proliferation of NECs, at least not at these
signalling steps. Generally, the process of differentiation
decreases the proliferation rate of stem cells. In fact, it has
been reported that a lowconcentration of Ab-(1–42) enhances
neuronal differentiation of adult NSCs (Heo et al., 2007). In
NSCs treated with GM1 and/or Ab-(1–40), however, expression
of nestin, a marker protein of NSCs, was not down-regulated
(Figures 5A and 5C). The number of cells positive for b-III
tubulin, a marker protein of mature neurons scarcely found in
untreated NECs, was not increased in GM1-a n dA b-(1–40)-
treated NECs (Figure 5B). MAP2, a marker protein of immature
and matureneurons, was notup-regulated in GM1- and Ab-(1–
40)-treated NECs (Figure 5C). These results indicate that the
NECs treated with GM1 and/or Ab-(1–40) were not differ-
entiated. On the other hand, it has been reported that Ab-(1–
40) and Ab-(1–42) induce apoptotic cell death in substantia
nigra/neuroblastoma cell line cells (Le et al., 1995) and adult
NSCs (Heo et al., 2007) respectively. As well, in NECs treated
with GM1 and/or Ab-(1–40), caspase 3 (a critical executioner of
apoptosis or programmed cell death signalling) was synergis-
tically activated(Figure 6A). It was confirmedthat a numberof
NECs treated with GM1 and Ab-(1–40) were positive for the
TUNEL assay, an indicator of cell death accompanied by DNA
fragmentation (Figures 6B and 6C). These results suggest that
the reduction of NEC number by GM1 and Ab-(1–40) was
Figure 2 Effects of high concentrations of GM1 and Ab-(1–40) on NECs
The number of NECs cultured in the presence of bFGF (0 or 5 ng/ml), GM1 (0 or
40 mM) and Ab-(1–40) (0 or 10 mM) for four days was estimated by the WST-
8 assay. Abs., absorbance.
Figure 3 Incorporation of exogenously added GM1 and Ab-(1–40) into
NECs
NECs were cultured in the presence of GM1 (0 or 40 mM) and FITC-Ab-(1–40)
(0 or 10 mM) for 2 days, and then stained with biotin-Ctxb and rhodamine-
conjugated streptavidin. Nuclei were stained with Hoechst 33258.
Figure 1 Effects of low concentrations of GM1 and Ab-(1–40) on NECs
The number of NECs cultured in the presence of bFGF (0 or 5 ng/ml), GM1 (0,
1, 5 or 10 mM) and Ab-(1–40) (0, 1 or 5 mM) for 4 days was estimated by the
WST-8 assay. bFGF was added as a mitogen of NECs. The absorbance (Abs.)
measured at a wavelength of 450 nm (reference: 650 nm) by this assay is
highly correlated with the number of living NECs.
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but not by the inhibition of proliferation or the induction of
differentiation, after incorporation into the NECs.
Figure 5 Neural lineage marker expression in NECs treated with GM1 and
Ab-(1–40)
Expression of (A) nestin (a marker protein of neural stem cells) and (B) b-III
tubulin (a marker protein of mature neurons) in NECs treated with GM1 (0 or
40 mM) and Ab-(1–40) (0 or 10 mM) for 3 days was analysed by cell staining.
Nuclei were stained with Hoechst 33258. (C) Expression of nestin and MAP2
(a marker gene of immature and mature neurons) in NECs treated with GM1 (0
or 40 mM) and Ab-(1–40) (0 or 10 mM) for 2 days was analysed by RT–PCR.
‘G3PDH’ indicates control GAPDH. ‘2RT’ indicates negative controls without
reverse transcription.
Figure 4 Cell proliferation signalling in NECs treated with GM1 and Ab-
(1–40)
(A) Activation of ERK (MAPK) in NECs treated with GM1 (0 or 40 mM) and Ab-
(1–40) (0 or 10 mM) for 2 days and then stimulated with bFGF (0 or 10 ng/ml)
for 10 min was analysed by Western blotting. bFGF was used as an inducer of
ERK activation. (B) Expression of p27
Kip1, a cyclin-dependent kinase inhibitor
up-regulated by ganglioside stimulation and involved in ganglioside-induced
inhibition of neural cell proliferation, in NECs treated with GM1 (0 or 40 mM)
and Ab-(1–40) (0 or 10 mM) for 2 days was analysed by Western blotting.
Figure 6 Apoptosis of NECs treated with GM1 and Ab-(1–40)
(A) Activation of caspase 3 (a critical executioner of apoptosis or programmed cell death signalling) in NECs treated with GM1 (0 or
40 mM) and Ab-(1–40) (0 or 10 mM) in the presence of bFGF (5 ng/ml) for 2 days was analysed by Western blotting. An inhibitor of N-
linked glycosylation, tunicamycin (1 mg/ml for 10 h), was used as a positive control to activate stress-mediated cell death signalling.
(B) Apoptotic cells in NECs treated with GM1 (0 or 40 mM) and Ab-(1–40) (0 or 10 mM) in the presence of bFGF (5 ng/ml) for 3 days
were detected with the TUNEL assay. Nuclei were stained with Hoechst 33258.( C) The proportion of TUNEL-positive cells in NECs
treated with or without GM1 and Ab-(1–40).
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53Our previous study using surface plasmon resonance and a
liposome capture method showed that GM1 directly bound to
Ab with high affinity (Ariga et al., 2001b). This finding
suggests that there is a possibility that sequestering Ab-(1–
40) with GM1 can inhibit the cytotoxic effect. To evaluate this
possibility, we pre-incubated Ab-(1–40) with GM1 to allow
their binding and then cultured NECs in the presence of this
pre-incubated mixture. However, the cytotoxic effect of Ab-
(1–40) was not inhibited by pre-incubation with GM1;1 0mM
of Ab-(1–40) pre-incubated with 40 mMo fG M1 drastically
reduced the NEC number (Figure 7). Thus we confirmed the
physical interaction between GM1 and Ab-(1–40) by the GM1
binding assay. First, we confirmed the efficiency of the assay
by detecting the interaction between GM1 and the well-
known ligand, Ctxb. As shown in Figure 8(A), this assay could
dose-dependently detect binding of Ctxb to GM1 immobilized
on 96-well plates. Then, we analysed the physical interaction
between GM1 and FITC-Ab-(1–40) using this assay. As shown
in Figure 8(B), FITC-Ab-(1–40) strongly interacts with GM1
only in the presence of cholesterol and sphingomyelin,
components of cell surface microdomains, as reported by
Kakio et al. (2001); the interaction between GM1 and FITC-Ab-
(1–40) was relatively weak in the absence of cholesterol and
sphingomyelin. This result suggests that GM1 itself could not
sequester Ab-(1–40) in vitro and reduce the cytotoxicity. So
far, the existence of cell surface microdomains, which are rich
in cholesterol and sphingomyelin, has been confirmed in NECs
(Yanagisawa et al., 2004). It is expected that exogenously
added GM1 is incorporated into NECs and distributed to the
cell surface microdomains. Binding of Ab-(1–40) to NECs and
activation of cell death signalling may occur in GM1-positive
microdomains.
As we have described, NECs are known to be rich in NSCs.
However, NECs are still a heterogeneous cell population
containing a few differentiated cells. To confirm the cytotoxic
effect of GM1 and Ab-(1–40) on NSCs, we prepared NSCs from
striata of mouse embryos in the form of neurospheres
(Figure 9A). These NSCs were confirmed to be positive for
the marker protein, nestin (Figure 9B). A number of GM1-a n d
Ab-(1–40)-treated NSCs were found to be positive in the
TUNEL assay (Figures 9C and 9D). These results indicate that
GM1 and 10 mMo fA b-(1–40) also have a cytotoxic effect on
NSCs.
DISCUSSION
In the present study, we clearly showed that GM1 and Ab-(1–
40) co-operatively have cytotoxic effects on NECs. This finding
suggests the possibility that a combination of Ab and GM1 is
cytotoxic to not only neurons, but also NSCs in AD brains. In
adult mammalian brains, GM1 is well known to be highly
expressed (Ngamukote et al., 2007; Yu et al., 2009). The
expression of GM1 may be involved in the impairment of
neurogenesis in the AD brains. It has been reported that neural
precursor cells isolated from post-mortem AD patient brains
exhibit a severe reduction in number during culture (Lovell et
al., 2006). Ab and GM1 may be involved in this reduction in the
Figure 7 Effects of Ab-(1–40) pre-incubated with GM1 on NECs
To evaluate whether the cytotoxic effect of Ab-(1–40) and GM1 can be
inhibited by sequestering, Ab-(1–40) (0 or 10 mM) was pre-incubated with
GM1 (0 or 40 mM) at 37˚C for 30 min to allow their binding. The number of
NECs cultured in N2-DMEM/F12 containing the Ab-(1–40) pre-incubated
with GM1 in the presence of bFGF (0 or 5 ng/ml) for 4 days was estimated by
the WST-8 assay. Abs., absorbance.
Figure 8 Physical interaction of GM1 and Ctxb (A) or Ab-(1–40) (B)
(A)G M1 (0, 1, 10, 100 or 1000 pmol per well) on polystyrene 96-well white
plates was incubated with 1 mM of biotin-Ctxb and then 2 mg/ml of Cy2-
conjugated streptavidin. (B)G M1 (0, 1 or 10 nmol per well), cholesterol (0 or
7.5 nmol per well) and sphingomyelin (0 or 7.5 nmol per well) on polystyrene
96-well white plates were incubated with 5 mM of FITC-Ab-(1–40). The
fluorescence intensities, which reflect the physical interaction of GM1 with
Ctxb or FITC-Ab-(1–40), were measured using a Victor
3 V multilabel plate
reader equipped with a lex5485 nm filter and a lem5535 nm filter.
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however, the involvement of gangliosides other than GM1
should also be considered. For instance, Abs have been
reported to bind to rat phaeochromocytoma, PC12 cells; the
binding does not seem to be with GM1, but rather with
fucosylated GM1, which is expressed (Yanagisawa et al., 2006b).
In addition, an in vitro study using surface plasmon resonance
clarified that a-series gangliosides (GQ1ba and GT1aa)a n d
b-series gangliosides (GQ1b,G T1b,G D3 and GD1b)a n dG D1a have
higher affinities for Ab than GM1 (Ariga et al., 2001b). More
importantly, a recent analysis of GD3 synthase-knockout mice
cross-bred with AD model mice has suggested that the bona
fide gangliosides initiating Ab aggregation in the AD brains are
b-series gangliosides, but not GM1 (Bernardo et al., 2009).
Therefore other gangliosides expressed in NECs such as GD3,
GQ1ba and GT1aa (Yanagisawa et al., 2004; Ngamukote et al.,
2007) may also increase the neurotoxic effects of Ab on NSCs
in the pathological condition of AD. Although there have been
many reports so far, the functional roles of Abs on NSCs are
still controversial, perhaps because of the ganglioside species
differentially expressed in these cells. Evaluation of the effects
of exogenous GM1 on neurogenesis and pathogenesis of AD
under pathological conditions, for instance using AD model
mice(Jankowskyet al.,2001),will beaninterestingand fruitful
subject for futurestudies.Thesestudies tounderstand the roles
of GM1 and Ab on NSCs in AD may contribute to the
development of new regenerative therapies for this disease.
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